We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Invitrogen has signed a definitive agreement to
acquire privately held molecular separation and purification technology pioneer
Dynal Biotech from majority owner Nordic Capital and a co-investor for approximately
NOK 2.5 billion.
The FDA has issued a public call for information on the use of color on pharmaceutical
labeling and packaging to determine if the practice is one that warrants further
action from the agency.
AstraZeneca's cancer treatment Iressa will be a main topic of discussion at
next month's meeting of the FDA's Oncologic Drugs Advisory Committee, which
will examine a recent clinical trial that raised questions about the drug's
effectiveness.
Recent FDA warnings about the use of antidepressants in
children appear to be having a significant effect on the number of pediatric
prescriptions for the drugs, according to an analysis by one of the nation's
largest pharmaceutical benefit managers.
As lawmakers and the FDA mull over proposals to address recent drug safety concerns,
pharmaceutical firms are hoping that any potential fix will not focus on the
premarket side of the equation, according to a top FDA official.
Genzyme has acquired Verigen, a private company based in Germany with a proprietary
cell therapy product for cartilage repair currently sold in Europe and Australia.
Auxilium Pharmaceuticals, a specialty pharmaceutical company that develops and
markets products for urologic and sexual health, has signed an additional licensing
agreement with PharmaForm.
Atugen AG, a biopharmaceutical company focused on development of siRNA-based
drugs, and ASINEX Ltd, a worldwide leader in lead generation and optimization
have entered into a long-term drug discovery and development collaboration.